Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 162
Filter
1.
HIV Med ; 20(3): 192-201, 2019 03.
Article in English | MEDLINE | ID: mdl-30620136

ABSTRACT

OBJECTIVES: The reported prevalence of chronic obstructive pulmonary disease (COPD) in people living with HIV (PLWHIV) varies widely. Our objective was to estimate the prevalence of airflow obstruction and COPD in unselected PLWHIV and identify characteristics that increase the risk of nonreversible airflow obstruction in order to guide case finding strategies for COPD. METHODS: All adults attending the Chronic Viral Illness Service were invited to participate in the study, regardless of smoking status or history of known COPD/asthma. Individuals underwent spirometric testing both before and after use of a salbutamol bronchodilator. Airflow obstruction was defined as forced expiratory volume in 1 s (FEV1 )/forced vital capacity (FVC) < 0.7 post-bronchodilation, whereas COPD was defined as FEV1 /FVC < 0.7 post-bronchodilation and Medical Research Council (MRC) score > 2. Multivariate logistic regression was used to evaluate risk factors associated with airflow obstruction, reported as adjusted odds ratios (aORs). RESULTS: Five hundred and three participants successfully completed spirometry testing. The median (Q1; Q3) age was 52 (44; 58) years. The median (Q1; Q3) CD4 count was 598 (438; 784) cells/µL and the median (Q1; Q3) nadir CD4 count was 224 (121; 351) cells/µL. There were 119 (24%) current smokers and 145 (29%) former smokers. Among those screened, 54 (11%) had airflow obstruction whereas three (1%) of the participants had COPD. Factors that were associated with airflow obstruction included a history of smoking [aOR 2.2; 95% confidence interval (CI) 1.1; 4.7], older age (aOR 1.6; 95% CI 1.2; 2.2), and lower CD4 count (aOR 0.8; 95% CI 0.7; 1.0). CONCLUSIONS: Airflow obstruction was relatively uncommon. Our findings suggest that PLWHIV who are ≥50 years old, smokers and those with nadir CD4 counts ≤ 200 cells/µL could be targeted to undergo spirometry to diagnose chronic airflow obstruction.


Subject(s)
Albuterol/administration & dosage , HIV Infections/complications , Pulmonary Disease, Chronic Obstructive/drug therapy , Pulmonary Disease, Chronic Obstructive/epidemiology , Adult , Albuterol/pharmacology , CD4 Lymphocyte Count , Canada/epidemiology , Cross-Sectional Studies , Female , Forced Expiratory Volume/drug effects , HIV Infections/immunology , Humans , Male , Middle Aged , Prevalence , Pulmonary Disease, Chronic Obstructive/etiology , Risk Assessment , Spirometry , Tertiary Care Centers , Vital Capacity/drug effects
2.
HIV Med ; 18(9): 655-666, 2017 10.
Article in English | MEDLINE | ID: mdl-28440036

ABSTRACT

OBJECTIVES: We sought to compare all-cause mortality of people living with HIV and accessing care in Canada and the UK. METHODS: Individuals from the Canadian Observational Cohort (CANOC) collaboration and UK Collaborative HIV Cohort (UK CHIC) study who were aged ≥ 18 years, had initiated antiretroviral therapy (ART) for the first time between 2000 and 2012 and who had acquired HIV through sexual transmission were included in the analysis. Cox regression was used to investigate the difference in mortality risk between the two cohort collaborations, accounting for loss to follow-up as a competing risk. RESULTS: A total of 19 960 participants were included in the analysis (CANOC, 4137; UK CHIC, 15 823). CANOC participants were more likely to be older [median age 39 years (interquartile range (IQR): 33, 46 years) vs. 36 years (IQR: 31, 43 years) for UK CHIC participants], to be male (86 vs. 73%, respectively), and to report men who have sex with men (MSM) sexual transmission risk (72 vs. 56%, respectively) (all P < 0.001). Overall, 762 deaths occurred during 98 798 person-years (PY) of follow-up, giving a crude mortality rate of 7.7 per 1000 PY [95% confidence interval (CI): 7.1, 8.3 per 1000 PY]. The crude mortality rates were 8.6 (95% CI: 7.4, 10.0) and 7.5 (95% CI: 6.9, 8.1) per 1000 PY among CANOC and UK CHIC study participants, respectively. No statistically significant difference in mortality risk was observed between the cohort collaborations in Cox regression accounting for loss to follow-up as a competing risk (adjusted hazard ratio 0.86; 95% CI: 0.72-1.03). CONCLUSIONS: Despite differences in national HIV care provision and treatment guidelines, mortality risk did not differ between CANOC and UK CHIC study participants who acquired HIV through sexual transmission.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , HIV Infections/mortality , Adult , Canada/epidemiology , Cohort Studies , Female , Humans , Male , Middle Aged , Observational Studies as Topic , Risk Factors , Sexually Transmitted Diseases, Viral/drug therapy , Sexually Transmitted Diseases, Viral/mortality , United Kingdom/epidemiology
3.
HIV Med ; 18(3): 151-160, 2017 03.
Article in English | MEDLINE | ID: mdl-27385643

ABSTRACT

OBJECTIVES: To document the quality of initial HIV care in Canada using the Programmatic Compliance Score (PCS), to explore the association of the PCS with mortality, and to identify factors associated with higher quality of care. METHODS: We analysed data from the Canadian Observational Cohort Collaboration (CANOC), a multisite Canadian cohort of HIV-positive adults initiating combination antiretroviral therapy (ART) from 2000 to 2011. PCS indicators of noncompliance with HIV treatment guidelines include: fewer than three CD4 count tests in the first year of ART; fewer than three viral load tests in the first year of ART; no drug resistance testing before initiation; baseline CD4 count < 200 cells/mm3 ; starting a nonrecommended ART regimen; and not achieving viral suppression within 6 months of initiation. Indicators are summed for a score from 0 to 6; higher scores indicate poorer care. Cox regression was used to assess the association between PCS and mortality and ordinal logistic regression was used to explore factors associated with higher quality of care. RESULTS: Of the 7460 participants (18% female), the median score was 1.0 (Q1-Q3 1.0-2.0); 21% scored 0 and 8% scored ≥ 4. In multivariable analysis, compared with a score of 0, poorer PCS was associated with mortality for scores > 1 [score = 2: adjusted hazard ratio (AHR) 1.64; 95% confidence interval (CI) 1.13-2.36; score = 3: AHR 2.02; 95% CI 1.38-2.97; score ≥ 4: AHR 2.14; 95% CI 1.43-3.21], after adjustments for age, sex, province, ART start year, hepatitis C virus (HCV) coinfection, and baseline viral load. Women, individuals with HCV coinfection, younger people, and individuals starting ART earlier (2000-2003) had poorer scores. CONCLUSIONS: Our findings further validate the PCS as a predictor of all-cause mortality. Disparities identified suggest that further efforts are needed to ensure that care is equitably accessible.


Subject(s)
HIV Infections/diagnosis , HIV Infections/drug therapy , Health Services Research , Quality of Health Care , Canada , HIV Infections/mortality
4.
HIV Med ; 16(2): 76-87, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25174373

ABSTRACT

OBJECTIVES: Sustained optimal use of combination antiretroviral therapy (cART) has been shown to decrease morbidity, mortality and HIV transmission. However, incomplete adherence and treatment interruption (TI) remain challenges to the full realization of the promise of cART. We estimated trends and predictors of treatment interruption and resumption among individuals in the Canadian Observational Cohort (CANOC) collaboration. METHODS: cART-naïve individuals ≥ 18 years of age who initiated cART between 2000 and 2011 were included in the study. We defined TIs as ≥ 90 consecutive days off cART. We used descriptive analyses to study TI trends over time and Cox regression to identify factors predicting time to first TI and time to treatment resumption after a first TI. RESULTS: A total of 7633 participants were eligible for inclusion in the study, of whom 1860 (24.5%) experienced a TI. The prevalence of TI in the first calendar year of cART decreased by half over the study period. Our analyses highlighted a higher risk of TI among women [adjusted hazard ratio (aHR) 1.59; 95% confidence interval (CI) 1.33-1.92], younger individuals (aHR 1.27; 95% CI 1.15-1.37 per decade increase), earlier treatment initiators (CD4 count ≥ 350 vs. <200 cells/µL: aHR 1.46; 95% CI 1.17-1.81), Aboriginal participants (aHR 1.67; 95% CI 1.27-2.20), injecting drug users (aHR 1.43; 95% CI 1.09-1.89) and users of zidovudine vs. tenofovir in the initial cART regimen (aHR 2.47; 95% CI 1.92-3.20). Conversely, factors predicting treatment resumption were male sex, older age, and a CD4 cell count <200 cells/µL at cART initiation. CONCLUSIONS: Despite significant improvements in cART since its advent, our results demonstrate that TIs remain relatively prevalent. Strategies to support continuous HIV treatment are needed to maximize the benefits of cART.


Subject(s)
Anti-HIV Agents/administration & dosage , HIV Infections/drug therapy , Medication Adherence/statistics & numerical data , Adult , Aged , Aged, 80 and over , CD4 Lymphocyte Count , Canada/epidemiology , Cohort Studies , Directive Counseling , Drug Administration Schedule , Drug Therapy, Combination , Follow-Up Studies , HIV Infections/epidemiology , HIV Infections/immunology , HIV Infections/psychology , Humans , Incidence , Medication Adherence/psychology , Middle Aged , Practice Guidelines as Topic , Risk Factors , Viral Load
5.
HIV Med ; 15(3): 153-64, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24304582

ABSTRACT

OBJECTIVES: Although combination antiretroviral therapy (cART) can restore CD4 T-cell numbers in HIV infection, alterations in T-cell regulation and homeostasis persist. We assessed the incidence and predictors of reversing these alterations with cART. METHODS: ART-naïve adults (n = 4459) followed within the Canadian Observational Cohort and exhibiting an abnormal T-cell phenotype (TCP) prior to cART initiation were studied. Abnormal TCP was defined as having (1) a low CD4 T-cell count (< 532 cells/µL), (2) lost T-cell homeostasis (CD3 < 65% or > 85%) or (3) CD4:CD8 ratio dysregulation (ratio < 1.2). To thoroughly evaluate the TCP, CD4 and CD8 T-cell percentages and absolute counts were also analysed for a median duration of 3.14 years [interquartile range (IQR) 1.48-5.47 years]. Predictors of TCP normalization were assessed using adjusted Cox proportional hazards models. RESULTS: At baseline, 96% of pateints had CD4 depletion, 32% had lost homeostasis and 99% exhibited ratio dysregulation. With treatment, a third of patients had normalized CD4 T-cell counts, but only 85 individuals (2%) had normalized their TCP. In a multivariable model adjusted for age, measurement frequency and baseline regimen, higher baseline CD4 T-cell counts and time-dependent viral suppression independently predicted TCP normalization [hazard ratio (HR) for baseline CD4 T-cell count = 1.42 (1.31-1.54) per 100 cells/µL increase; P ≤ 0.0001; HR for time-dependent suppressed viral load = 3.69 (1.58-8.61); P-value ≤ 0.01]. CONCLUSIONS: Despite effective cART, complete TCP recovery occurred in very few individuals and was associated with baseline CD4 T-cell count and viral load suppression. HIV-induced alterations of the TCP are incompletely reversed by long-term ART.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/immunology , HIV Infections/virology , HIV-1/drug effects , T-Lymphocytes/metabolism , Viral Load/drug effects , Adult , Antiretroviral Therapy, Highly Active/methods , CD4-CD8 Ratio , Canada , HIV Infections/drug therapy , Homeostasis , Humans , Male , Middle Aged , Phenotype , Proportional Hazards Models
6.
HIV Clin Trials ; 13(2): 90-102, 2012.
Article in English | MEDLINE | ID: mdl-22510356

ABSTRACT

BACKGROUND: The influence of chronic hepatitis C virus (HCV) infection on the risk, timing, and type of AIDS-defining illnesses (ADIs) is not well described. To this end, rates of ADIs were evaluated in a Canadian cohort of HIV seropositive individuals receiving highly active antiretroviral therapy (HAART). METHODS: ADIs were classified into 6 Centers for Disease Control and Prevention (CDC)-defined etiological subgroups: non-Hodgkin lymphoma, viral infection, bacterial infection, HIV-related disease, protozoal infection, and mycotic infection. Generalized estimating equation (GEE) Poisson regression models were used to estimate the effect of HCV on rates of ADIs after adjusting for covariates. RESULTS: Among 2,706 HAART recipients, 768 (28%) were HCV coinfected. Rates of all ADIs combined and of bacterial infection, HIV-related disease, and mycotic infection were increased in HCV-coinfected persons and among those with CD4 counts <200 cells/mm3 HCV was associated with an increased risk of ADIs (rate ratio [RR], 1.38; 95% CI, 1.01-1.88) and a 2-fold increased risk of mycotic infections (RR, 2.21; 95% CI, 1.35-3.62) in univariate analyses and after adjusting for age, baseline viral load, baseline CD4 count, and region of Canada. However, after further adjustment for HAART interruptions, HCV was no longer associated with an increased rate of ADIs overall (RR, 1.13; 95% CI, 0.80-1.59), but remained associated with an increased rate of mycotic infections (RR, 1.97, 95% CI, 1.08-3.61). CONCLUSION: Although HCV coin-fected individuals are at increased risk of developing ADIs overall, our analysis suggests that behavioral variables associated with HCV (including rates of retention on HAART), and not biological interactions with HCV itself, are primarily responsible.


Subject(s)
Acquired Immunodeficiency Syndrome/complications , Acquired Immunodeficiency Syndrome/drug therapy , Antiretroviral Therapy, Highly Active , HIV Infections/complications , HIV Infections/drug therapy , Hepatitis C, Chronic/complications , Adult , Anti-HIV Agents/administration & dosage , Anti-HIV Agents/therapeutic use , Canada/epidemiology , Cohort Studies , Coinfection , Female , HIV Infections/epidemiology , Hepatitis C, Chronic/epidemiology , Humans , Male , Middle Aged
7.
HIV Med ; 12(6): 352-60, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21059167

ABSTRACT

OBJECTIVE: The aim of the study was to evaluate time to virological suppression in a cohort of individuals who started highly active antiretroviral therapy (HAART), and to explore the factors associated with suppression. METHODS: Eligible participants were HIV-positive individuals from a multi-site Canadian cohort of antiretroviral-naïve patients initiating HAART on or after 1 January 2000. Viral load and CD4 measurements within 6 months prior to HAART initiation were assessed. Univariate and multivariate analyses were conducted using piecewise survival exponential models where time scale was divided into intervals (<10 months; ≥10 months). Virological suppression was defined as the time to the first of at least two consecutive viral load measurements <50 HIV-1 RNA copies/mL. RESULTS: A total of 3555 individuals were included in the study, of median age 40 years [interquartile range (IQR) 34-47 years]. Eighty per cent were male, 18% had a history of injecting drug use (IDU), and 13% presented with an AIDS-defining illness at baseline. The median time to suppression was 4.55 months (IQR 2.99-7.89 months). In multivariate analyses, older age, male sex, treatment in Ontario rather than British Columbia, non-IDU history, and having an AIDS diagnosis at baseline predicted increased likelihood of suppression. Patients with low baseline viral load were more likely to have suppression [4-5 log(10) copies/mL, hazard ratio (HR) 1.27, 95% confidence interval (CI) 1.18-1.38; <4 log(10) copies/mL, HR 1.49, 95% CI 1.32-1.68] than patients with baseline viral load ≥5 log(10) copies/mL; however, this effect ceased after 18 months of follow-up. Suppression was more likely with nonnucleoside reverse transcriptase inhibitors and ritonavir-boosted HAART. CONCLUSION: Identification of patients at risk for diminished likelihood of virological suppression will allow focusing of efforts and the utilization of resources to maximize the benefits of HAART.


Subject(s)
HIV Infections/immunology , HIV-1/immunology , RNA, Viral/immunology , Adult , Antiretroviral Therapy, Highly Active/methods , CD4 Lymphocyte Count , Canada/epidemiology , Cohort Studies , Female , HIV Infections/drug therapy , HIV Infections/epidemiology , Humans , Male , Middle Aged , RNA, Viral/drug effects , Treatment Outcome , Viral Load
8.
Clin Exp Immunol ; 161(3): 518-26, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20550549

ABSTRACT

Subcutaneous administration of intravenous immunoglobulin G (IgG) preparations provides an additional level of patient convenience and more options for patients with poor venous access or a history of intravenous IgG reactions. An open-label, pharmacokinetic trial (n = 32) determined the non-inferiority of the subcutaneous versus intravenous route of 10% caprylate/chromatography purified human immune globulin intravenous (IGIV-C; Gamunex®) administration by comparing the steady-state area under the concentration-versus-time curve (AUC) of total plasma IgG in patients with primary immunodeficiency disease. Patients on stable IGIV-C received two intravenous infusions (administered 3 or 4 weeks apart). Seven to 10 days after the second intravenous infusion, all patients switched to a weekly infusion of subcutaneous IGIV-C, with the dose equal to 137% of the previous weekly equivalent intravenous dose, for up to 24 weeks. Samples for pharmacokinetic analysis were collected during steady state for intravenous and subcutaneous IGIV-C treatments. The AUC(0-) τ geometric least-squares mean ratio was 0·89 (90% confidence interval, 0·86-0·92) and met the criteria for non-inferiority. The overall mean steady-state trough concentration of plasma total IgG with subcutaneous IGIV-C was 11·4 mg/ml, 18·8% higher than intravenous IGIV-C (9·6 mg/ml). Subcutaneous IGIV-C was safe and well tolerated. Subcutaneous IGIV-C infusion-site reactions were generally mild/moderate and the incidence decreased over time. No serious bacterial infections were reported. Weekly subcutaneous IGIV-C infusion using 137% of the weekly equivalent intravenous immunoglobulin dose provides an AUC comparable to intravenous administration, thus allowing patients to maintain the same IgG preparation/formulation if switching between intravenous and subcutaneous infusions.


Subject(s)
Immunoglobulin G/blood , Immunoglobulins, Intravenous/pharmacokinetics , Immunologic Deficiency Syndromes/drug therapy , Adolescent , Adult , Aged , Area Under Curve , Diarrhea/chemically induced , Dose-Response Relationship, Drug , Drug Administration Schedule , Humans , Immunoglobulins, Intravenous/administration & dosage , Immunoglobulins, Intravenous/adverse effects , Immunologic Deficiency Syndromes/metabolism , Immunologic Deficiency Syndromes/pathology , Immunologic Factors/administration & dosage , Immunologic Factors/pharmacokinetics , Immunologic Factors/therapeutic use , Infusions, Intravenous , Infusions, Subcutaneous , Metabolic Clearance Rate , Middle Aged , Respiratory Tract Infections/chemically induced , Sinusitis/chemically induced , Treatment Outcome , Young Adult
9.
HIV Med ; 8(7): 427-32, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17760734

ABSTRACT

OBJECTIVES: To determine the severity of injection site reactions (ISRs), patient quality of life (QoL) and preference when enfuvirtide is administered by the Biojector (Bioject, Medical Technologies, Inc., Tualatin, OR, USA) relative to standard needles. METHODS: A total of 201 HIV-positive patients on stable enfuvirtide-based therapy (n=184) or initiating such therapy (n=17) were evaluated prospectively after switching from standard needles to the Biojector system. Patients used needles for a minimum of 2 weeks prior to switching to the Biojector. Questionnaires to assess the incidence and severity of ISRs (31-item score) and QoL [Medical Outcomes Study HIV Health Survey (MOS-HIV)] were administered at baseline and following a minimum of 14 days of Biojector use. RESULTS: The median changes in ISR score and number of ISRs following a median of 1.0 month [interquartile range (IQR) 0.9, 1.3] of Biojector use were -3 (IQR -7, 1) and -1 (IQR -3, 1), respectively. The severity of pain (P<0.0001), induration (P<0.0001), pruritus (P<0.0001), nodules (P<0.0001) and erythema (P<0.0001) all decreased with the Biojector. Administration of enfuvirtide with the Biojector was associated with an improved patient QoL (P<0.0001), and was preferred by 72% of patients. CONCLUSIONS: Compared with needles, the Biojector was associated with a decreased severity of ISRs and improved QoL in patients taking enfuvirtide.


Subject(s)
HIV Envelope Protein gp41/administration & dosage , HIV Fusion Inhibitors/administration & dosage , HIV Infections/drug therapy , HIV , Peptide Fragments/administration & dosage , Adult , Area Under Curve , Enfuvirtide , Female , HIV Envelope Protein gp41/pharmacokinetics , HIV Fusion Inhibitors/pharmacokinetics , Humans , Injections/adverse effects , Male , Middle Aged , Patient Satisfaction , Peptide Fragments/pharmacokinetics , Prospective Studies , Quality of Life , Self Care , Therapeutic Equivalency
11.
Clin Nephrol ; 65(1): 13-21, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16429837

ABSTRACT

Indinavir is a potent HIV-1 protease inhibitor included in current antiretroviral therapeutic regimens. It is associated with renal and urological complications ascribed to indinavir crystalluria. We have previously reported that indinavir crystalluria is frequently observed soon after initiation of therapy. In a cohort of 54 asymptomatic indinavir-naive HIV-1-infected individuals during their first year of treatment with indinavir, approximately 25% of urinalyses (U/A) contained indinavir crystals. Because the determinants of the crystalluria are unknown, we examined the relationship between urine specific gravity (SG) and pH, singly and in combination, and indinavir crystalluria in these subjects. A total of 579 U/A were obtained from the study subjects at their scheduled monthly outpatient medical assessments. The frequency of indinavir crystalluria was lower in U/A with lower pH, irrespective of the SG. Conversely, U/A with high pH (> or = 6.0) had a higher frequency of indinavir crystalluria, which was further influenced by the urine SG. As a result, nearly half of the U/A (46.7%) with high pH (> or = 6.0) and intermediate-high SG (> or = 1.015) contained indinavir crystals. In conclusion, the frequency of indinavir crystalluria in asymptomatic HIV-1 infected individuals during their first year of treatment with indinavir was markedly influenced by the urine pH and SG. Our findings suggest that low urine pH may have a protective effect against indinavir crystalluria across the entire range of urine SG.


Subject(s)
Anti-HIV Agents/therapeutic use , Anti-HIV Agents/urine , HIV Infections/drug therapy , HIV Infections/urine , Indinavir/therapeutic use , Indinavir/urine , Adult , Aged , Anti-HIV Agents/adverse effects , Crystallization , Female , Humans , Hydrogen-Ion Concentration , Indinavir/adverse effects , Male , Middle Aged , Specific Gravity , Urinalysis , Urine
12.
Med Chem ; 1(2): 173-84, 2005 Mar.
Article in English | MEDLINE | ID: mdl-16787312

ABSTRACT

Quantitative Structure Activity Relationship (QSAR) techniques are used routinely by computational chemists in drug discovery and development to analyze datasets of compounds. Quantitative numerical methods like Partial Least Squares (PLS) and Artificial Neural Networks (ANN) have been used on QSAR to establish correlations between molecular properties and bioactivity. However, ANN may be advantageous over PLS because it considers the interrelations of the modeled variables. This study focused on the HIV-1 Protease (HIV-1 Pr) inhibitors belonging to the peptidomimetic class of compounds. The main objective was to select molecular descriptors with the best predictive value for antiviral potency (Ki). PLS and ANN were used to predict Ki activity of HIV-1 Pr inhibitors and the results were compared. To address the issue of dimensionality reduction, Genetic Algorithms (GA) were used for variable selection and their performance was compared against that of ANN. Finally, the structure of the optimum ANN achieving the highest Pearson's-R coefficient was determined. On the basis of Pearson's-R, PLS and ANN were compared to determine which exhibits maximum performance. Training and validation of models was performed on 15 random split sets of the master dataset consisted of 231 compounds. For each compound 192 molecular descriptors were considered. The molecular structure and constant of inhibition (Ki) were selected from the NIAID database. Study findings suggested that non-covalent interactions such as hydrophobicity, shape and hydrogen bonding describe well the antiviral activity of the HIV-1 Pr compounds. The significance of lipophilicity and relationship to HIV-1 associated hyperlipidemia and lipodystrophy syndrome warrant further investigation.


Subject(s)
Artificial Intelligence , Drug Design , HIV Protease Inhibitors/chemistry , Peptides/chemistry , Quantitative Structure-Activity Relationship , Algorithms , Computer Simulation , Databases as Topic , Genetics , HIV Protease/chemistry , HIV Protease/drug effects , HIV Protease Inhibitors/pharmacology , Least-Squares Analysis , Molecular Mimicry , Peptides/classification , Predictive Value of Tests
13.
J Immunol ; 171(1): 477-88, 2003 Jul 01.
Article in English | MEDLINE | ID: mdl-12817033

ABSTRACT

Both the magnitude and breadth of HIV-specific immunity were evaluated longitudinally on samples collected from six subjects starting highly active antiretroviral therapy (HAART) preseroconversion (group 1), 11 recently infected subjects starting HAART postseroconversion (group 2), five subjects starting HAART in the second half of the first year of infection (group 3), and six persons starting treatment in the chronic phase of infection (group 4). HIV-specific immunity was measured by IFN-gamma ELISPOT, detecting the frequency of cells responding to a panel of HLA-restricted HIV-1 peptides. Intracellular cytokine staining was used to detect the frequency of HIV-1 Gag p55-specific CD4(+) and CD8(+) T cells in a subset of participants. The magnitude and breadth of HIV-specific responses persisted in all group 1 subjects and in 5 of 11 (45%) group 2 subjects. Both of these parameters declined in 6 of 11 (55%) group 2 and in all group 3 and 4 individuals. All persons who maintained detectable numbers of HIV-1 Gag p55-specific CD4(+) and CD8(+) T cells after starting HAART preserved the intensity and breadth of their HIV-specific effector response. Our results show that HIV-specific immunity can be preserved even if HAART is initiated beyond the acute phase of infection.


Subject(s)
Antiretroviral Therapy, Highly Active , HIV Infections/drug therapy , HIV Infections/immunology , HIV-1/immunology , Adult , Age Factors , Amino Acid Sequence , CD4-CD8 Ratio , CD4-Positive T-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/metabolism , CD4-Positive T-Lymphocytes/virology , CD8-Positive T-Lymphocytes/drug effects , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/virology , Cell Line, Transformed , Female , HIV Infections/virology , Humans , Interferon-gamma/metabolism , Longitudinal Studies , Male , Middle Aged , Molecular Sequence Data , Retrospective Studies , Viral Load
14.
J Comput Chem ; 24(9): 1110-9, 2003 Jul 15.
Article in English | MEDLINE | ID: mdl-12759910

ABSTRACT

The relative energy between two different protonation sites of the Asp25' catalytic site residue is computed and analyzed for various HIV-1 Protease/inhibitor complexes and compared to the wild-type structure. By comparing calculations of negatively charged fragments of gradually increasing size up to 105 atoms we show that correct modeling of the HIV-1 Protease active site requires much larger models than the commonly used acetic acid/acetate moieties. The energy difference between the two proposed protonation sites decreases as the size of the system increases and tends to converge only when the entire catalytic triad of both monomers is taken into account. The importance of the Gly27 backbone amine groups in the stabilization of the negative charge within the catalytic site cleft is revealed. Comparison of the wild-type structure with the structures from various Pr/drug complexes indicates that the HIV-1 protease has a particular catalytic site flexibility.


Subject(s)
Amino Acids/chemistry , HIV Protease/chemistry , Models, Molecular , Protein Conformation , Catalytic Domain , Hydrogen Bonding , Molecular Structure , Thermodynamics
15.
Proc AMIA Symp ; : 320-4, 2002.
Article in English | MEDLINE | ID: mdl-12463839

ABSTRACT

Despite the proven clinical benefits of HAART, mortality may still occur; particularly in those with less than 50 CD4+ cells/mL and, in some cases, with a viral burden below detectable plasma levels of HIV-1 RNA. Multiple factors may predict mortality including initial response to therapy, viral factors and host immune parameters. Due to the complexity of this problem, we developed Artificial Intelligence based tools/Neural Network (NN) to optimally evaluate outcomes of therapy and predict morbidity and mortality. To further validate the accuracy of these tools, we challenged their performance with that of Cox regression modeling (RM). Our study population involved 116 HIV+ individuals who consistently maintained CD4+ count < 50 cells/mL for over 6 months. All patients were treated with antiretrovirals. To assess clinical outcomes, we developed a feedforward back-propagation Neural Network. We then compared the performance of this network to a Cox regression model. The Neural Network outscored the Cox regression model in the ROC curve areas: 0.888 vs 0.760 (HIV+ first Seropositivity to AIDS), 0.901 vs 0.758 (HIV+ first Seropositivity to Last Assessment incl. death) and 0.832 vs 0.799 (AIDS to Last Assessment incl. death), for the NN & Cox, respectively. In patients with a history of AIDS defining events and with severe T-Cell depletion, mortality occurs despite therapy. Although Neural Networks and Cox modeling were successful in predicting mortality, the Neural Network was superior in assessing risk in this population.


Subject(s)
HIV Seropositivity/mortality , HIV-1/immunology , Neural Networks, Computer , T-Lymphocytes/physiology , Biomarkers , CD4 Lymphocyte Count , HIV Seropositivity/immunology , HIV-1/genetics , Homeostasis , Humans , Predictive Value of Tests , Proportional Hazards Models , RNA, Viral , ROC Curve , Survival Analysis
16.
HIV Clin Trials ; 2(5): 438-44, 2001.
Article in English | MEDLINE | ID: mdl-11673819

ABSTRACT

PURPOSE: By protecting and stimulating HIV-specific CD4 cell responses, treatment of primary HIV infection (PHI) with potent quadruple HAART could lead to prolonged suppression of HIV replication after cessation of antiretroviral therapy. The QUEST trial investigates this hypothesis and aims to determine whether addition of a therapeutic vaccine to HAART increases the likelihood of prolonged viral suppression compared to HAART alone. METHOD: 148 patients with PHI were recruited. Participants were treated with open-label HAART for at least 76 weeks. Participants with sustained viremia <50 copies/mL were randomized to one of three 5-month, double-blinded study treatment groups: HAART alone, HAART + ALVAC-HIV (vCP1452), or HAART + ALVAC-HIV (vCP1452) + Remune. After a further month of HAART alone, all treatment was stopped where plasma HIV-1 RNA remained at <50 copies/mL. Intensive virologic and immunologic monitoring during a 24-week observation period followed treatment interruption. Patients who met treatment reintroduction criteria were offered HAART rescue.


Subject(s)
AIDS Vaccines/therapeutic use , Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , HIV Infections/therapy , HIV-1 , Antiretroviral Therapy, Highly Active , CD4-CD8 Ratio , Clinical Protocols , Combined Modality Therapy , Double-Blind Method , Drug Administration Schedule , Guidelines as Topic , HIV Infections/virology , HIV-1/genetics , Humans , RNA, Viral/blood , Viral Vaccines/therapeutic use , Viremia/prevention & control
17.
AIDS Res Hum Retroviruses ; 17(10): 887-900, 2001 Jul 01.
Article in English | MEDLINE | ID: mdl-11461675

ABSTRACT

Five HIV-seropositive twins were treated with HAART and given cycles of treatment consisting of adoptive cellular therapy from their HIV-seronegative identical twins followed by a 5-day course of intravenous IL-2. Changes in absolute and percent CD4(+) and CD8(+) cell count were monitored and compared with changes in these parameters occurring in seven age-, sex-, and disease stage-matched HIV-infected patients treated with HAART alone. Increase in the magnitude and breadth of HIV-specific immune responses was monitored in three twin subjects who received multiple treatment cycles. Absolute and percent CD4(+) cell counts rose dramatically and to significantly higher levels in the recipient twins than in control subjects treated with HAART only. The subjects who received multiple cycles of treatment developed new and increased levels of HIV-specific activated and memory cytotoxic T lymphocyte responses, and interferon gamma-secreting effector cells. Treatment consisting of HAART, adoptive cellular therapy, and IL-2 was superior to treatment with HAART alone for improving absolute and percent CD4(+) cell counts and inducing new, or increasing the magnitude of, HIV-specific immune responses in HIV infected patients.


Subject(s)
Antiretroviral Therapy, Highly Active , CD4-Positive T-Lymphocytes/immunology , HIV Infections/immunology , HIV Infections/therapy , Immunotherapy, Adoptive , Interleukin-2/therapeutic use , Adult , CD8-Positive T-Lymphocytes/immunology , Combined Modality Therapy , Diseases in Twins , Follow-Up Studies , HIV Infections/blood , HIV Seronegativity/immunology , HIV Seropositivity/blood , HIV Seropositivity/drug therapy , HIV Seropositivity/immunology , Humans , Immunoassay/methods , Interferon-gamma/metabolism , Lymphocyte Count , Male , Middle Aged , Pilot Projects , Twins, Monozygotic , Viral Load
18.
Trends Immunol ; 22(1): 17-20, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11286686

ABSTRACT

Itk/Emt, a tec family tyrosine kinase, is important for T-cell development and activation through the antigen receptor. Here, we review data suggesting that Itk/Emt is involved in the generation of critical second messengers (Ca(2+), PKC) whose duration it modulates by regulation of cytoskeletal reorganization. We propose that Itk/Emt constitutes an important link between these critical signaling events.


Subject(s)
Calcium Signaling , Cytoskeleton/enzymology , Cytoskeleton/immunology , Protein-Tyrosine Kinases/metabolism , Receptors, Antigen, T-Cell/physiology , Animals , Enzyme Activation/immunology , Humans , T-Lymphocytes/enzymology , T-Lymphocytes/metabolism
19.
J Immunol ; 166(1): 387-95, 2001 Jan 01.
Article in English | MEDLINE | ID: mdl-11123316

ABSTRACT

Tec, the prototypical member of the Tec family of tyrosine kinases, is abundantly expressed in T cells and other hemopoietic cell types. Although the functions of Itk and Txk have recently been investigated, little is known about the role of Tec in T cells. Using antisense oligonucleotide treatment to deplete Tec protein from primary T cells, we demonstrate that Tec plays a role in TCR signaling leading to IL-2 gene induction. Interestingly, Tec kinases are the only known family of tyrosine kinases containing a pleckstrin homology (PH) domain. Using several PH domain mutants overexpressed in Jurkat T cells, we show that the Tec PH domain is required for Tec-mediated IL-2 gene induction and TCR-mediated Tec tyrosine phosphorylation. Furthermore, we show that Tec colocalizes with the TCR after TCR cross-linking, and that both the Tec PH and Src homology (SH) 2 domains play a role in this association. Wortmannin, a phosphatidylinositol 3-kinase inhibitor, abolishes Tec-mediated IL-2 gene induction and Tec tyrosine phosphorylation, and partially suppresses Tec colocalization with the activated TCR. Thus, our data implicate the Tec kinase PH domain and phosphatidylinositol 3-kinase in Tec signaling downstream of the TCR.


Subject(s)
Blood Proteins/physiology , Phosphatidylinositol 3-Kinases/physiology , Phosphoproteins/physiology , Protein-Tyrosine Kinases/physiology , Sequence Homology, Amino Acid , Signal Transduction/immunology , T-Lymphocytes/enzymology , Amino Acid Substitution/genetics , Androstadienes/pharmacology , Animals , Arginine/genetics , Blood Proteins/genetics , Cysteine/genetics , Enzyme Inhibitors/pharmacology , Glutamic Acid/genetics , Humans , Interleukin-2/biosynthesis , Interleukin-2/genetics , Jurkat Cells , Lysine/genetics , Mice , Mice, Transgenic , Phosphatidylinositol Phosphates/metabolism , Phosphoinositide-3 Kinase Inhibitors , Phosphoproteins/genetics , Phosphorylation , Phosphotyrosine/metabolism , Protein Binding/genetics , Protein Binding/immunology , Protein Structure, Tertiary/drug effects , Protein Structure, Tertiary/genetics , Protein-Tyrosine Kinases/genetics , Protein-Tyrosine Kinases/metabolism , Receptor-CD3 Complex, Antigen, T-Cell/metabolism , Receptors, Antigen, T-Cell/antagonists & inhibitors , Receptors, Antigen, T-Cell/genetics , Receptors, Antigen, T-Cell/physiology , Signal Transduction/drug effects , Signal Transduction/genetics , T-Lymphocytes/immunology , T-Lymphocytes/metabolism , Transfection , Wortmannin
20.
Proc AMIA Symp ; : 249-53, 2001.
Article in English | MEDLINE | ID: mdl-11833478

ABSTRACT

Surrogate markers are by definition quantifiable laboratory variables that have clinical and biological relevance to disease outcomes. Virologic and immunologic surrogate markers have proven useful in following HIV-associated viral burden, immune dysregulation, dysfunction and deficiency. Monitoring of sequential changes in these markers and their interrelationships may provide significant information about viral-host-drug dynamics. The complexity and fluidity of these changes necessitates that an efficient means be developed for their monitoring. We therefore generated a neural network-based model for assessing host dynamics over time and compared its performance with that of a multiple regression model. Both modeling approaches were applied to the actual, non-filtered, clinical observations on 58 HIV-infected individuals treated consistently with Highly Active Anti-Retroviral Therapy (HAART), for a period of over-52 weeks resulting in an average of 16 observations per patient throughout this time span. Results demonstrated that the neural network was at least as accurate as a multi-regression model. Since our dataset was modest in size we also believe that neural networks warrant further consideration for modeling the complexity of HIV-host dynamics on larger datasets.


Subject(s)
Antiretroviral Therapy, Highly Active , HIV Infections/immunology , HIV Infections/virology , Neural Networks, Computer , Biomarkers , HIV Infections/drug therapy , Humans , Linear Models
SELECTION OF CITATIONS
SEARCH DETAIL
...